EOG Resources Inc (EOG)vsGlaxoSmithKline PLC ADR (GSK)
EOG
EOG Resources Inc
$130.03
-0.66%
ENERGY · Cap: $69.26B
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 39% more annual revenue ($32.78B vs $23.57B). EOG leads profitability with a 23.3% profit margin vs 17.8%. GSK appears more attractively valued with a PEG of 0.50. EOG earns a higher WallStSmart Score of 80/100 (A-).
EOG
Exceptional Buy80
out of 100
Grade: A-
GSK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.4%
Fair Value
$243.17
Current Price
$130.03
$113.14 discount
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 37.9%
Large-cap with strong market position
Keeps 23 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
15.6% revenue growth
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
Weak financial health signals
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EOG
The strongest argument for EOG centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 23.3% and operating margin at 37.9%. Revenue growth of 15.6% demonstrates continued momentum.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : EOG
The primary concerns for EOG are Piotroski F-Score.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
EOG profiles as a growth stock while GSK is a value play — different risk/reward profiles.
GSK carries more volatility with a beta of 0.30 — expect wider price swings.
EOG is growing revenue faster at 15.6% — sustainability is the question.
EOG generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
EOG scores higher overall (80/100 vs 66/100), backed by strong 23.3% margins and 15.6% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
EOG Resources Inc
ENERGY · OIL & GAS E&P · USA
EOG Resources, Inc. is an American energy company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in the Heritage Plaza building in Houston, Texas.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other OIL & GAS E&P Stocks
Want to dig deeper into these stocks?